Is Upstream Bio, Inc. (UPB) a Buy, Sell, or Hold?
NASDAQ : UPB
Upstream Bio, Inc.
$7.09 USD
-$0.35 (-4.7%)
- Volume
- 612.07K
- Average Volume
- 593.6K
- Market Capitalization
- $385.84M
- P/E Ratio
- -2.44
- Dividend Yield
- 0.00%
- Price Target
- $20.00
- Year High
- $33.68
- Year Low
- $5.85
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $27.99
Company Overview
NASDAQ
E. Rand Sutherland
Biotechnology
Healthcare
UPB
75
US
USD
Liquidity Metrics
0.00
27.99
27.99
7.95
0.00
Sales & Valuation
$2.85M
122.18
1.43
-2.83
-2.50
Profitability
-$2.66
-$143.44M
-4955.67%
-4955.67%
-48.40%
-55.66%
P/E Metrics
-2.44
0.08
0.08
Analyst Price Target & Rating
$20.00
$25.00
$15.00
2/5
3 Analysts
-64.55%
Financial Health Scores
15.16
2/9
$302.61M
$318.05M
$14.06M
-$156.76M
Key Metrics (TTM)
$309.27M
93.10
-1.98
23.14
-43.82%
-56.36%
-38.78%
-34.58%
-12624 days
Company Executives
| Name | Title |
|---|---|
| Adam Houghton | Chief Business Officer |
| Meggan Buckwell | Director of Corporate Communications & Investor Relations |
| Mersedeh Miraliakbari | Senior Vice President of Regulatory Affairs & Quality |
| Stacy Price | Chief Technology Officer |
| Lisa Fiering | Senior Vice President of People & Culture |
| Michael Paul Gray | Chief Financial Officer & Chief Operating Officer |
| Aaron Deykin | Chief Medical Officer and Head of Research & Development |
| Fang Xie | Vice President & Head of Biometrics |
| E. Rand Sutherland | Chief Executive Officer & Director |
| Allison Ambrose | Senior Vice President, General Counsel & Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Upstream Bio, Inc. (NASDAQ:UPB) Stock
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts. ...
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
2026-08-11 09:36:06
Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.74 per share a year ago.
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
2026-07-14 13:01:07
Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Fannie Mae Announces the Results of its Thirty-sixth Reperforming Loan Sale Transaction
2026-06-29 15:00:00
Fannie Mae Announces the Results of its Thirty-sixth Reperforming Loan Sale Transaction PR Newswire WASHINGTON,
2026-06-14 10:00:00
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –
KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust
2026-06-12 17:07:00
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 65 classes of mortgage pass-through notes from OBX 2026-AHC2 Trust, a prime agency-eligible RMBS transaction sponsored by Onslow Bay Financial LLC, that is fully originated and serviced by AmeriHome Mortgage Company, LLC (AmeriHome). This transaction is comprised of 599 residential mortgages with an aggregate unpaid principal balance (UPB) of approximately $340.0 million as of the June 1, 2026 cut-off date. The underlying collateral.
2026-06-10 13:52:10
Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-06-08 07:00:00
WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that additional data from its Phase 2 VIBRANT trial of verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented in an oral session at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Congress in Istanbul, Turkey, on Sunday, June 14, 2026.
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-03 07:00:00
WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m.
Frequently Asked Questions
-
What is the current Upstream Bio, Inc. (UPB) stock price?
-
Upstream Bio, Inc.(NASDAQ:UPB) stock price is $7.09 in the last trading session. During the trading session, UPB stock reached the peak price of $33.68 while $5.85 was the lowest point it dropped to. The percentage change in UPB stock occurred in the recent session was --4.7% while the dollar amount for the price change in UPB stock was -$0.35.
-
UPB's industry and sector of operation?
-
The NASDAQ listed UPB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of UPB?
-
Adam Houghton | Chief Business Officer
Meggan Buckwell | Director of Corporate Communications & Investor Relations
Mersedeh Miraliakbari | Senior Vice President of Regulatory Affairs & Quality
Stacy Price | Chief Technology Officer
Lisa Fiering | Senior Vice President of People & Culture -
How many employees does UPB have?
-
Number of UPB employees currently stands at 75. UPB operates from 890 Winter Street, Waltham, MA 02451, US.
-
Link for UPB official website?
-
Official Website of UPB is: https://upstreambio.com
-
How do I contact UPB?
-
UPB could be contacted at phone #781 208 2466 and can also be accessed through its website. UPB operates from 890 Winter Street, Waltham, MA 02451, US.
-
How many shares of UPB are traded daily?
-
The average number of UPB shares traded daily for last 3 months was 593.6K.
-
What is the market cap of UPB currently?
-
The market value of UPB currently stands at $385.84M with its latest stock price at $7.09